Premium
Effect of recombinant human thyroid‐stimulating hormone or levothyroxine withdrawal on salivary gland dysfunction after radioactive iodine administration for thyroid remnant ablation
Author(s) -
Iakovou Ioannis,
Goulis Dimitrios G.,
Tsinaslanidou Zinovia,
Giannoula Evanthia,
Katsikaki Grammatiki,
Konstantinidis Iordanis
Publication year - 2016
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.23974
Subject(s) - medicine , radioactive iodine , thyroid , sialadenitis , hormone , iodine , levothyroxine , incidence (geometry) , endocrinology , radiation therapy , thyroid stimulating hormone , ablation , salivary gland , urology , chemistry , physics , organic chemistry , optics
Background The purpose of this study was to examine the incidence of sialadenitis and xerostomia within a year after radioactive iodine administration for thyroid remnant ablation after preparation with recombinant human thyroid‐stimulating hormone (rhTSH) or levothyroxine (LT 4 ) withdrawal. Methods The study has included 121 patients, divided into 4 groups: group A (rhTSH = 100 mCi), group B (rhTSH = 70 mCi), group C (LT 4 withdrawal = 100 mCi), and group D (LT 4 withdrawal = 70 mCi). Study outcomes were Summated Xerostomia Inventory score and number of sialadenitis episodes after radioactive iodine administration. Results Salivary gland dysfunction was reported in 31% and 12% of patients, at the end of months 1 and 12, respectively. There was significantly lower incidence in groups A and B in comparison with groups C and D ( p = .002 and .021, respectively). Conclusion The use of rhTSH for preparation of radioactive iodine ablation as opposed to LT 4 withdrawal reduces the incidence of salivary gland dysfunction. © 2015 Wiley Periodicals, Inc. Head Neck 38 : E227–E230, 2016